Insights into HIV-1 Reverse Transcriptase (RT) Inhibition and Drug Resistance from Thirty Years of Structural Studies

Insights into HIV-1 Reverse Transcriptase (RT) Inhibition and Drug Resistance from Thirty Years of Structural Studies

The enzyme reverse transcriptase (RT) plays a central role in the life cycle of human immunodeficiency virus (HIV), and RT has been an important drug target. Elucidations of the RT structures trapping and detailing the enzyme at various functional and conformational states by X-ray crystallography h...

Полное описание

Библиографические подробности
Главные авторы:	Abhimanyu K. Singh, Kalyan Das
Формат:	Статья
Язык:	English
Опубликовано:	MDPI AG 2022-05-01
Серии:	Viruses
Предметы:	HIV-RT NRTI NNRTI drug design structural biology crystallography
Online-ссылка:	https://www.mdpi.com/1999-4915/14/5/1027

Схожие документы

Approved HIV reverse transcriptase inhibitors in the past decade
по: Guangdi Li, и др.
Опубликовано: (2022-04-01)

Mathematical Modelling of the Molecular Mechanisms of Interaction of Tenofovir with Emtricitabine against HIV
по: Sara Iannuzzi, и др.
Опубликовано: (2021-07-01)

The “Connection” Between HIV Drug Resistance and RNase H
по: Krista A. Delviks-Frankenberry, и др.
Опубликовано: (2010-07-01)

Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV
по: Oliver T. Stirrup, и др.
Опубликовано: (2019-10-01)

Development of HIV Drug Resistance in a Cohort of Adults on First-Line Antiretroviral Therapy in Tanzania during the Stavudine Era
по: Raphael Z. Sangeda, и др.
Опубликовано: (2021-11-01)

Identification of a 3-aminoimidazo[1,2-a]pyridine inhibitor of HIV-1 reverse transcriptase
по: Elleder Daniel, и др.
Опубликовано: (2012-12-01)

Efficacy and safety of novel russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors in first-line HIV treatment – 96-week study
по: A. V. Kravchenko, и др.
Опубликовано: (2018-07-01)

Diaryl ethers with carboxymethoxyphenacyl motif as potent HIV-1 reverse transcriptase inhibitors with improved solubility
по: Tomasz Frączek, и др.
Опубликовано: (2018-01-01)

APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants
по: Richa Dwivedi, и др.
Опубликовано: (2022-07-01)

Incidence and risk factors for neuropsychiatric events among Ghanaian HIV patients on long-term non-nucleoside reverse transcriptase inhibitor-based therapy
по: Fred S. Sarfo, и др.
Опубликовано: (2016-06-01)

Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors
по: Nicolas Sluis-Cremer, и др.
Опубликовано: (2013-11-01)

Chronic Hepatitis B Treatment Strategies Using Polymerase Inhibitor-Based Combination Therapy
по: Eriko Ohsaki, и др.
Опубликовано: (2021-08-01)

Picomolar inhibitor of reverse transcriptase featuring significantly improved metabolic stability
по: Ya-Li Sang, и др.
Опубликовано: (2023-07-01)

The long-term outcomes of antiretroviral treatment initiated with mono or dual nucleoside reverse transcriptase inhibitors in HIV-1-infected children: an Asian observational study
по: Orasri Wittawatmongkol, и др.
Опубликовано: (2015-07-01)

Development of fluorine-substituted NH2-biphenyl-diarylpyrimidines as highly potent non-nucleoside reverse transcriptase inhibitors: Boosting the safety and metabolic stability
по: Xin Jin, и др.
Опубликовано: (2023-03-01)

Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir
по: Hyeonah Byun, и др.
Опубликовано: (2024-12-01)

Anti‐HIV drugs reduce risk of prediabetes and progression to type 2 diabetes in HIV‐infected patients
по: Joseph Magagnoli, и др.
Опубликовано: (2023-06-01)

Scaffold Hopping in Discovery of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: From CH(CN)-DABOs to CH(CN)-DAPYs
по: Ting-Ting Li, и др.
Опубликовано: (2020-03-01)

Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Induced Neuropathy and Mitochondrial Toxicity: Limitations of the Poly-γ Hypothesis and the Potential Roles of Autophagy and Drug Transport
по: John Haynes, и др.
Опубликовано: (2024-12-01)

The Lysine 65 Residue in HIV-1 Reverse Transcriptase Function and in Nucleoside Analog Drug Resistance
по: Scott J. Garforth, и др.
Опубликовано: (2014-10-01)

Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase
по: Stefan G. Sarafianos, и др.
Опубликовано: (2010-02-01)

Drug Resistance in Non-B Subtype HIV-1: Impact of HIV-1 Reverse Transcriptase Inhibitors
по: Kamalendra Singh, и др.
Опубликовано: (2014-09-01)

Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data
по: Oliver T. Stirrup, и др.
Опубликовано: (2018-04-01)

Evaluation of the HIV-1 drug resistance to elsulfavirine and the effectiveness of it among Russian treatment-naïve patients
по: A. A. Kirichenko, и др.
Опубликовано: (2021-01-01)

Global Conformational Dynamics of HIV-1 Reverse Transcriptase Bound to Non-Nucleoside Inhibitors
по: Peter V. Coveney, и др.
Опубликовано: (2012-07-01)

Drosophila model of anti-retroviral therapy induced peripheral neuropathy and nociceptive hypersensitivity
по: Keegan M. Bush, и др.
Опубликовано: (2021-01-01)

Nucleoside Analog 2′,3′-Isopropylidene-5-Iodouridine as Novel Efficient Inhibitor of HIV-1
по: Ksenia Glumakova, и др.
Опубликовано: (2023-09-01)

NNRTI-induced HIV-1 protease-mediated cytotoxicity induces rapid death of CD4 T cells during productive infection and latency reversal
по: Benjamin Trinité, и др.
Опубликовано: (2019-06-01)

HIV drug resistance prediction with weighted categorical kernel functions
по: Elies Ramon, и др.
Опубликовано: (2019-07-01)

HIV medication to prevent fetal infection during pregnancy
по: Teodora Gabriela Cioroba, и др.
Опубликовано: (2022-03-01)

High frequency of Lamivudine and Telbivudine resistance mutations in hepatitis B virus isolates from human immunodeficiency virus co-infected patients on highly active antiretroviral therapy in Bucaramanga, Colombia
по: Henry Bautista-Amorocho, и др.
Опубликовано: (2023-07-01)

Anthrarufin and Its Anionic Moieties as Potential Inhibitors of HIV-1 Reverse Transcriptase (RT)
по: Svetlana Jeremić, и др.
Опубликовано: (2022-11-01)

K103N, V106M and Y188L Significantly Reduce HIV-1 Subtype C Phenotypic Susceptibility to Doravirine
по: Nikita Reddy, и др.
Опубликовано: (2024-09-01)

Virulence and Replicative Fitness of HIV-1 Transmitted/Founder (T/F) Viruses Harbouring Drug Resistance-Associated Mutation
по: Aanand Sonawane, и др.
Опубликовано: (2024-11-01)

Machine learning aided multiscale modelling of the HIV-1 infection in the presence of NRTI therapy
по: Huseyin Tunc, и др.
Опубликовано: (2023-03-01)

Targeting the Structural Maturation Pathway of HIV-1 Reverse Transcriptase
по: Thomas W. Kirby, и др.
Опубликовано: (2023-11-01)

The Molecular Docking of Specific Reverse Transcriptase Inhibitory Ligands onto the Molecular Model of HIV-1 Reverse Transcriptase
по: Roohallah Yousefi
Опубликовано: (2024-06-01)

Virtual screening, molecular docking studies and DFT calculations of FDA approved compounds similar to the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz
по: Maryam A. Jordaan, и др.
Опубликовано: (2020-08-01)

Structure-Based Discovery and Characterization of a Preclinical Drug Candidate for the Treatment of HIV-1 Infection
по: Dongwei Kang, и др.
Опубликовано: (2022-10-01)

Transmitted drug resistance to rilpivirine among antiretroviral‐naïve patients living with HIV from northern Poland
по: Miłosz Parczewski, и др.
Опубликовано: (2014-01-01)